A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.

ABSTRACT: To determine the impact of tocilizumab, a monoclonal antibody against the interleukin 6 receptor, on survival in patients with coronavirus disease 2019.

Design

Observational cohort study of patients hospitalized with coronavirus disease 2019 between March 1, 2020, and April 24, 2020. A propensity-matched (1:1) analysis was used to compare patients who received tocilizumab to controls who did not. Competing risk survival analysis was used to determine the primary outcome of time to mortality, and adjusted log-linear and logistic regression for secondary outcomes.

Setting

Three hospitals within the NYU Langone Health system in New York.

Patients

Consecutive adult patients hospitalized with coronavirus disease 2019.

Intervention

Tocilizumab 400-mg IV once in additi

SUBMITTER: Lewis TC 

PROVIDER: S-EPMC7671881 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature